Jpmorgan Chase & CO Calliditas Therapeutics Ab Transaction History

Jpmorgan Chase & CO

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 12, 2024	BUY	$15.79 - $28.99 $6,694 - $12,291	424 Added 231.69%	607 $15,000
Q3 2023 Nov 14, 2023	SELL	$15.68 - $20.38 $2,853 - $3,709	-182 Reduced 49.86%	183 $3,000
Q2 2023 Aug 11, 2023	BUY	$15.7 - $25.61 $5,730 - $9,347	365 New	365 $5,000
Q4 2022 Feb 13, 2023	SELL	$11.5 - $19.6 $736 - $1,254	-64 Reduced 17.25%	307 $5,000
Q3 2022 Nov 14, 2022	SELL	$14.12 - $22.49 $1,157 - $1,844	-82 Reduced 18.1%	371 $6,000
Q2 2022 Aug 11, 2022	BUY	$12.85 - $20.36 $269 - $427	21 Added 4.86%	453 $8,000
Q1 2022 May 11, 2022	SELL	$15.14 - $25.55 $1,453 - $2,452	-96 Reduced 18.18%	432 $8,000
Q4 2021 Feb 10, 2022	BUY	$15.04 - $26.32 $7,941 - $13,896	528 New	528 $13,000

825K

8.5K

26.6K

Ticker CALT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 26,624,800
Market Cap $1.06B
Description
Calliditas Therapeutics AB (publ), a clinical-stage biopharmaceutical company, focused on identifying, developing, and commercializing pharmaceuticals products for treatments in orphan indications with initial focus on renal and hepatic diseases. It offers Nefecon, an oral formulation of budesonide that is an immunosuppressant for the treatment ...

Get notified when there are updates to the investment portfolio of Jpmorgan Chase & CO, based on Form 13F filings with the SEC.

Stay updated on Jpmorgan Chase & CO with notifications on news.